Lexaria Bioscience (LEXX) Capital Expenditures (2010 - 2026)

Lexaria Bioscience has disclosed Capital Expenditures across 15 years of filings, most recently posting $40816.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $40816.0, up 4081500.0% year-over-year; the trailing twelve-month figure through Feb 2026 was $40816.0 (down 39.67% YoY), and the FY2025 annual result was $24646.0, down 42.7% from the prior year.
• Capital Expenditures came in at $40816.0 for Q1 2026 at Lexaria Bioscience, up from $1.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $43014.0 in Q3 2024 to a low of -$1.0 in Q2 2025.
• The 5-year median for Capital Expenditures is $10030.5 (2022), against an average of $14904.1.
• Across the five-year window, Capital Expenditures plunged 100.0% in 2025 and soared 4081500.0% in 2026, its largest moves.
• Lexaria Bioscience's Capital Expenditures stood at $20500.0 in 2022, then tumbled by 35.38% to $13248.0 in 2023, then jumped by 86.03% to $24645.0 in 2024, then tumbled by 100.0% to $1.0 in 2025, then jumped by 4081500.0% to $40816.0 in 2026.
• The last three Capital Expenditures figures came in at $40816.0 (Q1 2026), $1.0 (Q3 2025), and -$1.0 (Q2 2025), per Business Quant data.